CAS: 1380392-05-1

JMS-17-2

5-(3-(4-(4-Chlorophenyl)Piperidin-1-Yl)Propyl)Pyrrolo[1,2-A]Quinoxalin-4(5H)-One

JMS-17-2 is a small molecule that was shown to have a potent and selective inhibitory effect on the production of chemokines in cancer cells. It blocks the interaction between CXCL12 and its receptor, CXCR4. This interaction is important for normal bone tissue development and function, as well as for chemotaxis and metastasis of cancer cells. JMS-17-2 has been shown to prevent tumor growth in animal models by inhibiting angiogenesis, or the formation of new blood vessels to supply nutrients to tumors. The drug also inhibits tumor growth by decreasing the number of primary tumors, reducing bone lesions, and inhibiting the progression of pancreatic cancer. Clinical trials are currently being conducted to assess the efficacy of JMS-17-2 in humans with advanced solid tumors.

JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).